Skip Navigation

Nephrology Dialysis Transplantation 2004 19(12):2952-2954; doi:10.1093/ndt/gfh577
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fliser, D.
Right arrow Articles by Haller, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fliser, D.
Right arrow Articles by Haller, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant Vol. 19 No. 12 © ERA-EDTA 2004; all rights reserved

Editorial Comment

Cardiovascular disease in renal patients—a matter of stem cells?

Danilo Fliser, Kirsten de Groot, Ferdinand Hermann Bahlmann and Hermann Haller

1 Department of Internal Medicine, Hannover Medical School, Hanover, Germany

Correspondence and offprint requests to: Danilo Fliser, MD, Division of Nephrology, Department of Internal Medicine, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany. Email: fliser.danilo@mh-hannover.de

Keywords: cardiovascular disease; endothelial progenitor cells; haematopoietic progenitor cells; renal failure

The first 10% of the full text of this article appears below.



   Stem cells in cardiovascular medicine
 
Stem cells have emerged as a new exciting therapeutic option for a variety of conditions in cardiovascular medicine such as myocardial infarction, heart failure and peripheral vascular disease. The encouraging results from recent experimental and animal studies are currently being tested in several clinical trials, focusing mainly on the treatment of patients with acute myocardial infarction and/or heart failure [1–4]. For this purpose, mostly bone marrow-derived mononuclear cells (BMCs) have been obtained directly from the patient's bone marrow by aspiration and eventually expanded ex vivo before intra-coronary or even intravenous (i.v.) application. The majority of these rather small studies primarily explored the feasibility and safety of this experimental . . . [Full Text of this Article]



   Endothelial progenitor cells—what are they and what can they do?
 


   EPCs in patients with renal disease
 


   Can we modulate the number of regenerative EPCs?
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
H. Zhang, A. Zhang, D.E. Kohan, R.D. Nelson, F.J. Gonzales, T. Yang, C. Schmidt-Lucke, L. Rossig, S. Fichtlscherer, M. Vasa, et al.
Edema and Congestive Heart Failure from Thiazolidone Insulin Sensitizers--Excess Sodium Reabsoption in the Collecting Duct: Collecting Duct-Specific Deletion of Peroxisome Proliferator-Activated Receptor {gamma} Blocks Thiazolidinedione-Induced Fluid Retention. Proc Nat Acad Sci U S A 102: 9406-9411, 2005
J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3139 - 3142.
[Full Text] [PDF]